---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-016364"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:00:49.875621+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Reviva Q1 net loss $7.4M; FDA alignment on brilaroxazine NDA path

## Summary
- Net loss approximately $7.4M ($0.25 per share) for Q1 2024 vs $6.9M ($0.31 per share) for Q1 2023.
- Cash $12.0M as of March 31, 2024, down from $23.4M at December 31, 2023.
- FDA aligned on registrational Phase 3 program for brilaroxazine in schizophrenia; RECOVER-2 trial start expected Q2 2024.
- Topline data from 1-year OLE trial expected Q4 2024; potential NDA submission targeted for Q4 2025.
- Company initiated Phase 3 RECOVER-1 data presentations at SIRS and ASCPT meetings in Q1 2024.

## SEC filing metadata
- accession: 0001437749-24-016364
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774924016364/0001437749-24-016364-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774924016364/rvph20240510_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-016364
- JSON: https://secwatch.observer/filing/0001437749-24-016364.json
- Plain text: https://secwatch.observer/filing/0001437749-24-016364.txt

## Key facts
- Earnings Releases
  REVIVA PHARMACEUTICALS HOLDINGS, INC. reported first quarter ended March 31, 2024 results: net income approximately $7.4 million, EPS $0.25 per share.
  - Period: first quarter ended March 31, 2024
  - Net income: approximately $7.4 million
  - EPS: $0.25 per share
  - Result: reported results
  source text: The Company reported a net loss of approximately $7.4 million, or $0.25 per share, for the three months ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1742927/000143774924016364/0001437749-24-016364-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.